1. Scrip
  2. >>Advanced Therapies
  3. >>Cell Therapies

Medipost Accelerates Global Push For Lead Stem Cell Therapy

ASEAN, Japan On Near-Term Radar

 
• By Jung Won Shin

South Korean stem cell therapy company Medipost is speeding up the entry of flagship product Cartistem into global markets, with an initial focus on ASEAN countries and Japan and helped by regulators' allowance of early local trials to be waived on the back of strong Korean data.

Stem cells on colorful background, 3D illustration
Asian Progress For Medipost's Lead Cell Therapy • Source: Shutterstock

Medipost Co., Ltd. is gearing up for the market entry and commercialization of its flagship stem cell therapy Cartistem in Malaysia and Japan, as local regulatory authorities there have accepted existing clinical data from the South Korea bioventure's home market, meaning that some local trials can be waived.

Cartistem, an allogeneic, umbilical cord blood-derived mesenchymal stem cell therapy, is used for the treatment of knee cartilage defects in patients with osteoarthritis (with ICRS grade IV cartilage defect) caused by degeneration or repetitive trauma

More from Cell Therapies

More from Advanced Therapies

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

 
• By Alaric DeArment

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.